
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc is poised for substantial growth as its Alzheimer's candidate, PMN310, shows a promising safety profile, lacking the amyloid-related imaging abnormalities (ARIA) that have impacted other therapies, which may enhance its market potential. The ongoing Phase Ib PRECISE-AD study is progressing rapidly, with more than 85% enrollment completed, positioning the company to release substantial data by mid-2026, further validating its therapeutic approach. With a massive and growing commercial opportunity in the Alzheimer's market, the continued positive developments in PMN310 reinforce a favorable outlook for the company's stock.
Bears say
ProMIS Neurosciences Inc reported a significant net loss of $11.6 million in 3Q25, equating to a loss of $0.24 per share, which underscores ongoing financial challenges. The company faces multiple risks that threaten its future, including the potential failure of PMN310 to demonstrate safety and efficacy in clinical trials, as well as the risk of needing to raise additional funds before achieving cash flow positivity. Additionally, competition in the market is intensifying, which may hinder market uptake of its therapies and could lead to future partnership uncertainties.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares